FCGRT and myasthenia gravis: Patients with MuSK+ MG respond poorly to pyridostigmine and eculizumab is only indicated in AChR+ MG (7, 8), although the recently approved FcRn rozanolixizumab-noli is indicated for both MuSK+ and AChR+ subtypes (10).